Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00358839

Enrollment

Registered

2006-08-01

Start date

2006-07-31

Completion date

2006-10-31

Last updated

2006-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial Hemiplegic Migraine

Keywords

Familial hemiplegic migraine type 1 and 2, CGRP, middle cerebral artery, superficial temporal artery, headache, genotype, Healthy Volunteers

Brief summary

The aim of the present study is to explore functional consequences of migraine gene mutations on their responses to Calcitonin Gene Related Peptide (CGRP)infusion.

Detailed description

Calcitonin Gene Related Peptide (CGRP) induces migraine attacks indistinguishable from spontaneous attacks in approximately 50% of migraine sufferers. Treatment of spontaneous migraine attacks with an antagonist to CGRP is effective in many patients. These data show that CGRP is involved in both initiation and maintenance of migraine attack. The consequence of migraine gene mutations on relevant migraine pathways has never been tested. The aim of the present study is to explore functional consequences of migraine gene mutations on their responses to CGRP infusion. The project will improve our understanding of the neurobiology of migraine and stimulate development of new treatment targets.

Interventions

DRUGCGRP

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

ECT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

Patients: Diagnosis of familial hemiplegic migraine (IHS-classification criteria) caused by mutations in the CACNA1A gene and the ATP1A2 gene. Controls: Healthy volunteers

Exclusion criteria

Controls: No primary headache in their own history 2) Patients and controls: * A history of cerebrovascular disease and other CNS- disease * A history of serious somatic and mental disease * A history suggesting ischaemic heart disease * A history of hypo- or hypertension * Daily intake of medication apart from oral contraceptives * Abuse of alcohol or medicine (opioid analgesics). * Pregnant or breastfeeding women. On the study day: * No intake of a simple analgesic in the previous 48 hours * No headache in the previous 48 hours

Design outcomes

Primary

Measure	Time frame
headache and associated symptoms	—
blood flow velocity of the middle cerebral artery	—
diameter of the superficial temporal artery	—

Secondary

Measure	Time frame
MAP	—
HR	—

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026